Fibrotic Drivers and the 26-Gene Signature
How melatonin's proposed condensate-linked gene set overlaps with fibrosis, EMT, YAP/TAZ, β-catenin, and stromal remodelling
In oncology, fibrosis is not just scar tissue.
It is part of the desmoplastic survival program around the tumour.
That includes ECM deposition, collagen cross-linking, CAF activation, EMT pressure, tissue stiffening, and therapy resistance.
Where fibrosis fits in the condensate model
Fibrotic signalling sits mainly across two domains.
Axis I: nuclear condensates that switch fibrotic gene programs on
Axis II: state-transition condensates that drive EMT, invasion, and stromal adaptation
That is why fibrosis, EMT, and phase separation overlap so strongly in this model.
The main pathways in view are not obscure.
They are the familiar pro-fibrotic cancer drivers:
TGF-β or SMAD
YAP or TAZ
Wnt or β-catenin
EMT transcription factors
epigenetic programs that lock these states in place
Fibrosis-linked genes highlighted here
SMAD3
SMAD3 is a core TGF-β effector.
It drives collagen, fibronectin, and ECM-related transcription.
It fits directly into Axis I nuclear condensate models.
It helps run fibrotic transcription programs rather than just touching them indirectly.
TWIST1
TWIST1 is a major EMT driver.
It supports invasion, mesenchymal transition, and fibrotic remodelling.
It also fits the enhancer-hub logic behind EMT and fibroblast-like transition states.
VIM
Vimentin marks and supports mesenchymal states.
It links cell mechanics, invasion, and stromal-style behaviour.
That matters in desmoplastic and metastatic niches where tumour cells take on more fibroblast-like features.
YAP1 and WWTR1 (TAZ)
These are central mechano-sensitive regulators.
They connect tissue stiffness, fibroblast activation, EMT, and enhancer-level transcription.
They are especially relevant where the matrix itself helps lock malignant behaviour in place.
CTNNB1 (β-catenin)
β-catenin helps maintain Wnt-driven transcription, EMT, and fibroblast activation.
It also shows phase-separation relevance in nuclear signalling hubs.
It cooperates with both YAP or TAZ and TGF-β in fibrotic remodelling.
EZH2 and KDM1A (LSD1)
These epigenetic enzymes help lock fibrotic and EMT programs in place.
That makes them important to the idea of transcriptional memory inside condensate-like hubs.
They are part of the reason these states can become durable rather than temporary.
Why this matters for melatonin
The melatonin literature already contains repeated anti-fibrotic and anti-EMT findings.
These include effects on:
TGF-β or SMAD signalling
TWIST1 and vimentin expression
YAP or TAZ activity
oxidative and inflammatory drivers of fibroblast activation
The 26-gene condensate signature gives those findings a more structural frame.
It suggests melatonin may not just block single pathways.
It may also make the fibrotic transcription hubs themselves less stable.
Why these genes matter together
These genes are not interesting only one by one.
They help describe a tissue state.
That state includes stromal activation, mechanical stiffening, EMT pressure, redox adaptation, and transcriptional persistence under stress.
When those signals cluster together, the tumour gains a more durable survival niche.
That is why a condensate-based view adds value here.
It explains how many pro-fibrotic signals can reinforce each other physically, not just biochemically.
How the anti-fibrotic literature lines up
Across tumour and non-tumour fibrosis models, melatonin is repeatedly linked to:
lower TGF-β or SMAD3 activity
lower EMT pressure, including TWIST1 and vimentin patterns
lower YAP or TAZ signalling
lower oxidative and inflammatory activation of fibroblast-like states
lower activation pressure on CAF and myofibroblast behaviour
That does not prove condensate disruption directly in patients.
It does show that the anti-fibrotic literature and the condensate framework point in the same direction.
Practical summary
This is still a mechanistic model.
It does, however, help connect several older observations into one picture:
melatonin reduces fibrotic signalling
melatonin reduces EMT pressure
melatonin changes redox and stress handling
those same processes help sustain oncogenic condensates
Related pages
Melatonin in Oncology - Study Notes — the hub page that ties together the mitochondria, dosing, immune, phase-separation, and fibrosis sections
Phase Separation in Oncology — the oncogenic-condensate model, its three levers, and the chronotherapy angle
Moderate-Dose Immune Effects and Timing — the human oral adjunct literature, Th1 logic, and timing framework
Dosing, Bioavailability, and Human Scaling — how mouse and cell data translate into estimated human exposure, route limits, and bioavailability caveats
High-Dose Mitochondria, RET, and ROS — the mechanistic RET, ROS, uncoupling, and apoptosis sequence behind the high-dose claim
Key references
Phase separation and cancer review
https://www.nature.com/articles/s41392-022-01076-xMelatonin and cancer metabolism review
https://pubmed.ncbi.nlm.nih.gov/35803926/Additional condensate-linked cancer paper
https://www.sciencedirect.com/science/article/pii/S2589004226007959Melatonin and Hippo-pathway cross-talk
https://onlinelibrary.wiley.com/doi/full/10.1002/mba2.58Melatonin and cancer-treatment review with EMT context
https://www.oncotarget.com/article/16379/text/